文献速递腹部泌尿生殖MR

疑似急性胆道梗阻管理中的风险分层与非风险分层诊断检查:比较有效性、成本及MR胰胆管成像的作用

Risk-stratified versus Non-Risk-stratified Diagnostic Testing for Management of Suspected Acute Biliary Obstruction: Comparative Effectiveness, Costs, and the Role of MR Cholangiopancreatography.
PubMed 文献 · Radiology · 2017-03-16

该决策分析模型比较了非增强MR胰胆管成像、增强MR成像/MR胰胆管成像与ASGE风险分层指南三种策略在疑似胆总管结石患者中的成本效果。风险分层策略成本更低但效果较差;非增强MR胰胆管成像在45-55岁患者中最具成本效果,55岁以上患者采用ASGE指南可最大化QALY且成本最低。

要点

  • 55岁以上疑似急性胆道梗阻患者采用ASGE风险分层指南评估可最大化QALY且成本最低。
  • 年轻患者可能受益于MR胰胆管成像而非风险分层诊断检查,因其对胆总管结石和替代病因检出更优。
  • 风险分层策略较MR胰胆管成像长期节省1870美元和2068美元,但QALY分别降低0.1814和0.1831。

核心结论

  • 55岁以上成人采用ASGE指南评估最优,年轻疑似急性胆道梗阻患者可能受益于MR胰胆管成像而非风险分层诊断检查,因其对胆总管结石和胆道梗阻替代病因的检出更优。

研究设计与样本

  • 决策分析模型,从美国卫生系统视角比较三种诊断策略在疑似胆总管结石患者中的成本与效果,时间跨度1年和终身;成本基于Medicare报销;敏感性分析评估参数变异对模型结果的影响。

诊断标准与关键数值

  • 非增强MR胰胆管成像在45-55岁患者中最具成本效果(每获得质量调整生命年低于100 000美元);风险分层检查较非增强和增强MR胰胆管成像分别长期节省1870美元和2068美元,但QALY分别降低0.1814和0.1831;非增强MR胰胆管成像的终身增量成本每QALY为10 311美元;20-44岁患者胆道狭窄或恶性肿瘤检验前概率0%-73%时增强MR成像更受青睐。

临床应用与阅片要点

  • 作者认为55岁以上成人采用ASGE指南评估最优,年轻患者可能受益于MR胰胆管成像而非风险分层诊断检查。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To analyze the cost-effectiveness of the American Society for Gastrointestinal Endoscopy (ASGE) risk stratification guidelines versus magnetic resonance (MR) cholangiopancreatography-based treatment of patients with possible choledocholithiasis. Materials and Methods A decision-analytic model was constructed to compare cost and effectiveness of three diagnostic strategies for gallstone disease with possible choledocholithiasis: noncontrast MR cholangiopancreatography, contrast material-enhanced MR imaging/MR cholangiopancreatography, and ASGE risk stratification guidelines for diagnostic evaluation recommending endoscopy (high risk), MR cholangiopancreatography (intermediate risk), or no test (low risk). Analysis was performed from a U.S. health system perspective over 1-year and lifetime horizons. The model accounted for benign and malignant causes of biliary obstruction and procedural complications. Cost information was based on Medicare reimbursements. Sensitivity analysis assessed the impact of parameter variability on model results. Results Noncontrast MR cholangiopancreatography was most cost-effective in 45-55-year-old patients (less than $100 000 per quality-adjusted life-year [QALY] gained), while contrast-enhanced MR imaging was favored in younger adults. Risk-stratified testing was less costly than MR cholangiopancreatography, with long-term savings of $1870 and $2068 versus noncontrast and contrast-enhanced MR cholangiopancreatography, respectively, but was also less effective (-0.1814, -0.1831 QALY, respectively). The lifetime incremental cost per QALY for noncontrast MR cholangiopancreatography was $10 311. Contrast-enhanced MR imaging was favored with pretest probabilities of biliary stricture or malignancy 0%-73% for patients aged 20-44 years. For patients older than 55 years, ASGE guidelines maximized QALYs at the lowest cost. Conclusion Although adults older than 55 years of age are optimally evaluated by using ASGE guidelines, younger patients suspected of having acute biliary obstruction likely benefit from MR cholangiopancreatography rather than risk-stratified diagnostic imaging because of improved detection of choledocholithiasis and alternative causes of biliary obstruction. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kang SK, Hoffman D, Ferket B, et al. Risk-stratified versus Non-Risk-stratified Diagnostic Testing for Management of Suspected Acute Biliary Obstruction: Comparative Effectiveness, Costs, and the Role of MR Cholangiopancreatography. Radiology. 2017. PMID: 28301778. doi:10.1148/radiol.2017161714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。